



A)




B)




Appendix 9, as supplied by the authors. Appendix to: Yau K, Chan CT, Abe KT, et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. *CMAJ* 2022. doi: 10.1503/cmaj.211881. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

C)



D)



Supplementary Appendix 9: Bootstrapped median difference in SARS-CoV-2 antibody levels (mRNA-1273 minus BNT162b2) for (A) anti-Spike 6-7 weeks (B) anti-RBD 6-7 weeks (C) anti-Spike 12 weeks (D) anti-RBD 12 weeks after second dose.

NOTE: 95% confidence intervals are indicated in dashed lines.